Macrolides (Clarithromycin or Azithromycin) are the oral antibiotics that provide dual coverage for common skin pathogens and non-tuberculous mycobacteria

For skin and soft tissue infections requiring NTM coverage, macrolides—specifically clarithromycin or azithromycin—are the only oral antibiotics that reliably cover both typical skin pathogens (including MRSA) and non-tuberculous mycobacteria. 1, 2

Why Macrolides Are the Answer

NTM Coverage

Macrolides are the cornerstone of all NTM treatment regimens 1, 2
For M. avium complex: Azithromycin (preferred) or clarithromycin with rifampin and ethambutol 2
For M. abscessus complex: Daily oral macrolide (preferably azithromycin) as part of intensive and continuation phases 2
For M. chelonae: 100% susceptibility to clarithromycin 1
Critical caveat: Macrolide monotherapy should NEVER be used for NTM—it leads to resistance 2

Skin Pathogen Coverage

Macrolides (specifically clarithromycin) cover common skin pathogens including streptococci and some staphylococci 3
Erythromycin 250 mg four times daily is listed for impetigo, though resistance in S. aureus and S. pyogenes may occur 3
Azithromycin has documented efficacy in cat-scratch disease (cutaneous bacillary angiomatosis) 3

Alternative Oral Agents With Partial NTM Activity

Doxycycline/Minocycline

Limited NTM activity: Only 25% of M. chelonae isolates are susceptible to doxycycline 1
Good skin pathogen coverage: 100 mg twice daily for MSSA and MRSA 3
Not reliable for NTM treatment but may have adjunctive role 1

Linezolid

Approximately 50% of M. abscessus isolates are susceptible 1
90% of M. chelonae isolates susceptible 1
Excellent MRSA coverage: 600 mg twice daily 3
Major limitation: Severe side effects with long-term use (anemia, peripheral neuropathy, nausea) at standard doses 1
Lower dose (600 mg daily) may reduce toxicity while maintaining antimycobacterial activity 1

Moxifloxacin

Has activity against atypical mycobacteria associated with dermatologic infections 4
Used as adjunctive oral agent in M. abscessus continuation phase 2
Good skin pathogen coverage including anaerobes 5
Not first-line for NTM but may be added to multidrug regimens 2

Clinical Algorithm for Selection

If NTM skin infection is suspected or confirmed:

Never use monotherapy—always multidrug regimen 2
For M. avium complex skin/soft tissue:
- Azithromycin (preferred) or clarithromycin + rifampin + ethambutol 2
- Consider IV amikacin initially if severe or disseminated 2
For M. abscessus complex skin/soft tissue:
- Intensive phase: Oral macrolide (azithromycin preferred) + IV amikacin + IV tigecycline/imipenem/cefoxitin for 3-12 weeks 2
- Continuation phase: Oral macrolide + inhaled amikacin + 2-3 oral agents (minocycline, clofazimine, moxifloxacin, linezolid) 2
For M. marinum (sporotrichoid pattern):
- Clarithromycin or azithromycin-based regimen 6
- Often requires prolonged treatment (mean >300 days for some species) 6

Critical Pitfalls to Avoid

Do not use azithromycin monotherapy if NTM is suspected—this rapidly induces macrolide resistance 2
If patient is already on azithromycin for CF or other indication, stop it immediately while evaluating for NTM disease 2
Clarithromycin resistance is emerging: 40% of MABC strains in recent studies 6
Always obtain susceptibility testing before finalizing treatment regimen 2
Immunocompromised patients (38% of NTM SSTI cases) require more aggressive therapy and longer duration 6
Misdiagnosis is common: 82.6% of NTM SSTI initially diagnosed as skin tuberculosis or bacterial infection 6

Bottom Line

Macrolides (clarithromycin or azithromycin) are the only oral antibiotics that reliably cover both common skin pathogens and NTM, but they must always be used as part of a multidrug regimen when treating NTM infections. For empiric coverage of suspected NTM skin infection while awaiting cultures, start a macrolide-based multidrug regimen rather than monotherapy. 1, 2

Which oral antibiotic provides coverage for common skin pathogens and also non‑tuberculous mycobacteria?

Have a follow-up question?